Jeffrey M. Leiden, Executive Chairman of Vertex Pharmaceuticals (VRTX), has demonstrated a pronounced selling bias in his recent insider transactions, with no open-market purchases recorded in the past year. Since November 2025, Leiden has executed 17 sales totaling over $82.3 million, dwarfing his lifetime buy total of $12 million. The bulk of this activity occurred in concentrated bursts: on December 3, 2025, he sold $27.6 million worth of shares across 11 transactions, followed by another $23.6 million in sales on November 14, 2025. More recently, he disposed of $1.43 million on February 18, 2026, and $1.72 million on February 24, 2026. These disposals were primarily coded as open-market sales (Form 4 code "S"), with smaller amounts attributed to option exercises ("M") and awards ("A").
Leiden’s trading pattern shows consistent divestment in Vertex, the only company in which he has reported transactions. The absence of any buys since at least November 2025—coupled with the scale and frequency of sales—suggests a deliberate reduction in exposure. Notably, his largest single-day liquidation occurred on December 3, 2025, when he sold shares across multiple price points, with individual transactions ranging from $515,000 to $7.09 million. While the filings don’t specify reasons for the sales, the sheer volume and recurring nature indicate a strategic unwind rather than isolated portfolio rebalancing. The continued activity into early 2026 reinforces this trend, with no indication of a shift toward accumulation.
AI-assisted summary